Neuronetics Releases Financial and Operational Results for Q3 2025 and Unveils CEO Transition Strategy
Financial Performance: Neuronetics reported Q3 2025 revenue of $37.3 million, an 11% increase on an adjusted pro forma basis compared to Q3 2024, with significant growth in Greenbrook clinic revenue, which reached $21.8 million, a 25% increase year-over-year.
Operational Highlights: The company achieved over 229,429 global patients treated and received $10 million in additional funding under a debt agreement, while New York State Medicaid expanded coverage for TMS therapy, enhancing access for over 5 million members.
Leadership Transition: CEO Keith J. Sullivan announced his intention to retire on June 30, 2026, after five years of leadership, during which he played a key role in the strategic acquisition of Greenbrook TMS.
Future Outlook: Neuronetics anticipates Q4 2025 revenue between $40 million and $43 million, with a target for positive cash flow from operations, while adjusting full-year revenue expectations to between $147 million and $150 million.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on STIM
About STIM
About the author
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
TRICARE West Broadens NeuroStar® TMS Coverage to Support Adolescents 15 and Older Facing Depression
TRICARE Coverage Expansion: Neuronetics, Inc. announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, benefiting military families in multiple states.
Significance of TMS for Adolescents: The expansion of TMS coverage is seen as a crucial step in providing effective treatment for adolescents struggling with depression, especially given the limited medication options available.
NeuroStar's Unique Position: NeuroStar is the first TMS company with FDA clearance for adolescent treatment and has a dedicated health policy team advocating for further access to TMS therapy.
Impact on Mental Health: With an estimated 4.3 million U.S. adolescents affected by major depression, NeuroStar Advanced Therapy offers a non-invasive treatment option that can significantly improve quality of life when traditional medications fail.
